| Name | Title | Contact Details |
|---|
Founded in 2013, Palm Medical Centers is a provider of value-based, capitated primary care services with a focus on high-quality clinical outcomes, cost-effective care, and a patient-centric experience. Operating a network of 19 medical centers across five counties in Florida, PMC serves more than 34,000 Medicare Advantage and managed Medicaid patients. Partnering with numerous managed care organizations, Palm Medical Centers offers comprehensive and integrated medical care to plan members with a focus on quality. In addition to primary care services, the company coordinates cardiology, dentistry, optometry, pediatrics, podiatry, psychiatry and other specialist services. Palm Medical Centers continues to seek partnership opportunities with high quality providers in existing and new markets.
Health Risk Management, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Quality Electrodynamics is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Globespan Medical, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.